Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Extracellular vesicle digital scoring assay for assessment of treatment responses in hepatocellular carcinoma patients.

Chen Zhao, Yi-Te Lee, Jacqueline Ziqian Yang et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16321

e16321 Background: There are no validated biomarkers for assessing hepatocellular carcinoma (HCC) treatment response (TR). Extracellular vesicles (EVs) ar...

Belantamab mafodotin plus lenalidomide/dexamethasone in newly diagnosed intermediate-fit & frail multiple myeloma patients: Long-term efficacy and safety from the phase 1/2 BELARD clinical trial.

Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos et al. Jun 01, 2025 pp. 7512-7512 10.1200/jco.2025.43.16_suppl.7512

7512 Background: We report the long-term safety & efficacy results of a novel, extended dosing schedule of belantamab mafodotin (belamaf) combined wit...

Board certification and billing practices of international medical graduate hematologists and oncologists.

Austin Wesevich, Liam J. Schmitt, Michael Wesevich Jun 01, 2025 pp. 9007-9007 10.1200/jco.2025.43.16_suppl.9007

9007 Background: International medical graduates (IMGs) comprise a substantial portion of the oncology workforce in the United States (US). IMGs may help...

Outcomes of heart failure hospitalizations among patients with malignant carcinoid tumors.

Dileep Kumar Reddy Regalla, Ayobami Gbenga Olafimihan, Ferdinand Ugwuja Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16356

e16356 Background: Malignant carcinoid tumor (MCT) is a neuroendocrine neoplasm which is estimated to affect the heart in about 50% of patients. Carcinoid...

The TRADE study: A phase 2 trial to assess the tolerability of abemaciclib dose escalation in early-stage HR+/HER2- breast cancer.

Erica L. Mayer, Dario Trapani, Se Eun Kim et al. Jun 01, 2025 pp. 517-517 10.1200/jco.2025.43.16_suppl.517

517 Background: The CDK4/6 inhibitor abemaciclib (abema) is approved with adjuvant endocrine therapy (ET) for high-risk node positive hormone receptor pos...

Practice patterns related to ovarian function suppression in the SWOG S2010 clinical trial of young women with breast cancer.

Norah Lynn Henry, Joseph M. Unger, Amy Darke et al. Jun 01, 2025 pp. 522-522 10.1200/jco.2025.43.16_suppl.522

522 Background: Addition of ovarian function suppression (OFS) to adjuvant endocrine therapy (ET) improves disease free survival for young patients at hig...

The optimal choice and combination strategy of vascular-targeting therapy for patients with advanced soft tissue sarcoma: A systematic review and network meta-analysis.

Yan Wang, Hangcheng Xu, Qiang Sa et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23532

e23532 Background: Soft tissue sarcomas (STS) are rare, heterogeneous tumors with poor prognosis, often characterized by high recurrence rates and limited...

Carfilzomib, iberdomide, and dexamethasone (KID) in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): Updated results from phase 1/2 study.

Noa Biran, David H. Vesole, Harsh Parmar et al. Jun 01, 2025 pp. 7553-7553 10.1200/jco.2025.43.16_suppl.7553

7553 Background: SOC regimens for patients (pts) with transplant-eligible NDMM include VRd, D-VRd, and KRd. Iberdomide, a cereblon modulator, enhances imm...

Molecular features of breast cancer metastatic to gynecologic sites.

Jody Lee Wellcome, Sharon Wu, Matthew James Oberley et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13032

e13032 Background: Breast Cancer (BC) is the leading cause of cancer-related deaths among women worldwide. Both molecularly and histologically, BC is a he...

Five-year follow-up results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab (pembro) for the treatment of clear cell renal cell carcinoma (ccRCC).

Naomi Balzer Haas, Thomas Powles, Piotr Tomczak et al. Jun 01, 2025 pp. 4514-4514 10.1200/jco.2025.43.16_suppl.4514

4514 Background: KEYNOTE-564 (NCT03142334) established pembro monotherapy as the first adjuvant regimen to significantly i...

A novel proteomics-based approach for detection of ESR1 mutant peptides in hormone receptor positive metastatic breast cancer: An exploratory study from India.

Shanthala Siddappa, Usha Amirtham, Linu Abraham Jacob et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15175

e15175 Background: ESR1 gene mutation is a commonly implicated mechanism of endocrine resistance in metastatic breast cancers (MBCs). Though many mutation...

Multicenter study of the impact of trial eligibility criteria on enrollment to KRAS G12C inhibitor trials in patients with non-small cell lung cancer.

Michael S. May, Margaux Wooster, Prashasti Agrawal et al. Jun 01, 2025 pp. 11171-11171 10.1200/jco.2025.43.16_suppl.11171

11171 Background: Eligibility criteria (EC) are the primary method to assess patient appropriateness for clinical trials....

Comprehensive genomic profiling in AYA cancer patients.

Naomi Hayashi, Naoki Miyazaki, Ippei Fukada et al. Jun 01, 2025 pp. 11144-11144 10.1200/jco.2025.43.16_suppl.11144

11144 Background: Cancer types in Adolescents and Young Adults (AYA) vary by age. Since many AYA cancers are classified as rare, patients continue to face...

Frontline brentuximab vedotin (BV) and CHP in patients (pts) with peripheral T-cell lymphoma (PTCL) with <10% CD30 expression: Primary analysis results from the phase 2 SGN35-032 study.

Swaminathan P. Iyer, Deepa Jagadeesh, Eva Domingo-Domenech et al. Jun 01, 2025 pp. 7077-7077 10.1200/jco.2025.43.16_suppl.7077

7077 Background: BV, an antibody-drug conjugate targeting CD30, has shown single-agent activity in lymphomas with low CD30 expression. The combination of...

Histopathologic and demographic features of non-small cell lung cancer in patients with <i>BRCA</i> pathogenic germline variants.

Benjamin Aaron Bleiberg, Michael Wang, Caitlin Orr et al. Jun 01, 2025 pp. 10573-10573 10.1200/jco.2025.43.16_suppl.10573

10573 Background: Patients with pathogenic germline variants (PGVs) in BRCA1 and BRCA2 ( BRCA1...

Neoadjuvant dose-dense anthracycline and cyclophosphamide in combination with carboplatin, paclitaxel, and pembrolizumab for triple-negative breast cancer: A systematic review and meta-analysis.

Vitor Teixeira Liutti, David Laios do Vale, Bruno Lins de Souza et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e12606

e12606 Background: Pembrolizumab in combination with carboplatin and paclitaxel (CT), followed by 3-weekly anthracycline and cyclophosphamide (AC), or adm...

Dietary risk factors associated with colorectal polyp risk and potential for progression to malignancy.

Melissa Rachel Goldin, Xiangzhu Zhu, Ken S. Lau et al. Jun 01, 2025 pp. 3626-3626 10.1200/jco.2025.43.16_suppl.3626

3626 Background: Colorectal polyp development and progression to cancer are associated with diet and microbial dysbiosis. Red and processed meat intakes h...

Patterns of management of positive sentinel lymph nodes in breast cancer patients after the American College of Surgeons Oncology Group Z0011 trial: A retrospective cohort.

Mohamad Hadi El Charif, Malak Ghezzawi, Hazem Assi et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e12584

e12584 Background: The ACOSOG-Z0011 clinical trial introduced significant changes to the traditional surgical management of early breast cancer with posit...

Artificial intelligence-based prediction of claudin 18.2 expression and immune phenotype to guide treatment decisions in patients with gastric cancer.

Hyung-Don Kim, Soo Ick Cho, Jinho Shin et al. Jun 01, 2025 pp. 4047-4047 10.1200/jco.2025.43.16_suppl.4047

4047 Background: With the increasing availability of immune checkpoint inhibitor (ICI)- and targeted agent-based treatments for gastric cancer, evaluating...

MRI-based radiomic signature and its association with genomic complexity in breast tumor heterogeneity.

Joonoh Lim, Young Seok Ju, Jeong Seok Lee et al. Jun 01, 2025 pp. 563-563 10.1200/jco.2025.43.16_suppl.563

563 Background: Breast cancer is inherently heterogeneous, posing challenges for effective treatment. Uncovering the relationship between imaging features...

Association of MammaPrint and clinical outcomes by race among 5000 individuals with HR+HER2- early stage breast cancer enrolled in FLEX.

Erin Frances Cobain, Priyanka Sharma, Kent Hoskins et al. Jun 01, 2025 pp. 11147-11147 10.1200/jco.2025.43.16_suppl.11147

11147 Background: Black women with hormone receptor-positive (HR+), HER2-negative (HER2-) early stage breast cancer (EBC) have a 38% higher mortality rate...

Impact of muscle mass loss on survival during neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma: A multi-center retrospective study in China (TIMES study).

Jie Zhu, Guiyu Huang, Wencheng Zhang et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16106

e16106 Background: The value of excessive muscle loss (EML) during neoadjuvant chemoradiotherapy (NCRT) in patients with locally advanced esophageal squam...

Post-treatment MRI to predict pathological complete response in triple-negative breast cancer following neoadjuvant chemoimmunotherapy.

Toulsie Ramtohul, Derek Lollivier, Justine Spriet et al. Jun 01, 2025 pp. 590-590 10.1200/jco.2025.43.16_suppl.590

590 Background: Neoadjuvant chemoimmunotherapy (NACI) has significantly improved pathological complete response (pCR) rates in early-stage triple-negative...

Social genomic mechanisms of health disparities among adolescent/young adult survivors of Hodgkin and non-Hodgkin lymphoma: ECOG-ACRIN EAQ211.

Brad J. Zebrack, Fenghai Duan, Steven W. Cole et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps12137

TPS12137 Background: Research in human genomics maps molecular pathways through which social and psychological factors regulate gene expression in immune...

Enhancing team efficiency for genetic risk assessment: Medical oncology-led germline testing for pancreatic cancer.

Salwan Al Mutar, Neha Barrows, Hussna Abunafeesa et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23243

e23243 Background: Pancreatic adenocarcinoma is an aggressive cancer with a 13% five-year survival rate. To prolong survival, early implementation of trea...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page